News
Article
10 I 26 pharmind
The Gold Standard in Medical Device Advertising
How much scientific evidence is required for the advertising of a medical device?
Anyone who promotes therapeutic effects must be able to substantiate them with scientifically sound evidence. But can the “gold standard” developed for pharmaceuticals be applied without reservation to medical devices? For example, how are placebo-controlled, double-blind studies supposed to be conducted for implants when ethical and practical limitations stand in the way?
My colleague Dominik Kollmar from our Bad Homburg office and I address these questions in our latest article, “The Gold Standard in Medical Device Advertising,” in the trade journal “die pharmazeutische industrie.”
The focus is on three practical aspects:
🔹 Scientific validation requires a nuanced approach. The specific characteristics of the respective medical device and the specific claim being advertised must be taken into account. A blanket application of the requirements from the pharmaceutical sector falls short.
🔹 CE certification is not an official drug approval. However, it can serve as a significant indicator of the scientific validity of an advertising claim, if that claim was the subject of the relevant review in the conformity assessment procedure. Case law on this matter has not yet been consistent.
🔹 Particular care must be taken with “Data on File” and when citing studies. Unpublished internal studies must be clearly identifiable as such. Likewise, limitations on the validity of a study must not be overlooked in advertising.
For manufacturers, this means: scientific evidence, regulatory documentation, and promotional communications must be carefully coordinated. This creates legal certainty and strengthens confidence in medical innovations.
04 I 26 RPG
An Interview with Alexander Ehlers on the Future of Primary Care
How can we ensure reliable, cross-sector care for patients? This question is the focus of an interview by Alexander P. F. Ehlers with Nikolaus Huss in the current issue (4/2026) of the journal *Recht und Politik im Gesundheitswesen* (RPG).
Under the title “The German Health Care System: Restructuring, Competition, and Accountability,” the two will discuss the necessary structural and financial changes in the German healthcare system. The focus is in particular on better coordination between outpatient and inpatient care, funding oriented toward the entire course of treatment, and the question of the future role of the legislature, self-governance, and competition.
The interview appeared in RPG, Volume 32, Issue 4/2026, on pages 82–85.
